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The human  major histocompatibility region, HLA-D, controls the expression of a 
number  of polymorphic antigens exhibiting limited tissue  distribution. Two  sets of 
antigens,  SB  and  DR,  controlled by separate  loci within  the  HLA-D  region  (1-3), 
exhibit similar functions relating to antigen presentation and T  cell regulation (4-7). 
Recent  studies  have  demonstrated  that  a  mo;~oclonal  antibody,  I-LR1,  is  reactive 
with  some of the  allelic products  of the SB locus  (8).  Using the  I-LR1  antibody to 
isolate SB  antigens,  it has been  shown  that  the  two  chains resemble the  alpha and 
beta chains of the DR  antigens in molecular weight as measured by sodium dodecyl 
sulfate (SDS)  gel electrophoresis (9).  These and other parallels between  SB and DR 
antigens suggest a  structural relationship between the two sets of antigens. This study 
describing a  portion of the amino-terminal amino acid sequences of these molecules 
delineates that  relationship and  suggests that  the  alpha and  beta chains  of the  SB 
antigens  are structurally distinct  from  the  DR  alpha and  beta chains  and  that  SB 
antigens, like DR antigens, are homologues of the murine I-E antigens. 
Materials  and  Methods 
Cells. The human Epstein-Barr virus-transformed lymphoblastoid B cell line, PRIESS (DR4/ 
4)  (10),  was  obtained  from  J.  Kaufman,  Harvard  University,  Cambridge,  MA.  The  SB 
phenotype of this line (SB3/4) was established by primed lymphocyte typing using the same 
cellular reagents and general techniques previously described (11); however, like other lympho- 
blastoid cell lines used as stimulator cells, PRIESS was inactivated by treatment with mitomycin 
C and was used at a lower stimulator cell concentration (2). 
Monoclonal Antibodies.  The monoclonal antibodies I-LR1 and IIIE3 have been described (8, 
9,  12). Their ability to bind to human cells was examined using the method of Williams (13). 
Previous  studies  (8)  of  I-LR1  (by  population  association  and  by  studies  of  antibody 
inhibition) indicated that I-LR1 binds to SB3 but not to SB4 allelic products. The inference 
that  I-LR1  would  bind  to  SB3  but  not  SB4  on  PRIESS  was  confirmed  by  experiments 
demonstrating that the response of SB3-primed cells to PRIESS was inhibited (>50%) by the 
addition of I-LR1 antibody, but the response of SB4-primed cells to PRIESS was not inhibited 
(<10%)  (8).  I-LR1  was unable  to block cellular binding of an  anti-DR antibody, IIIE3, to 
PRIESS (Gabriel Nunez, personal communication). 
IIIE3 was not able to inhibit SB-specific proliferation using techniques previously described 
(8). Prior studies indicate that IIIE3 appears to recognize a subset of DR antigens (12). 
Isolation of Radiolabeled Antigens.  Cells were radiolabeled in culture with  [3H]amino acids, 
lysed with Nonidet P-40, and affinity purified on a lentil lectin column to isolate a glycoprotein 
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pool as previously described (12). 
Antibody Affinity Columns.  Immunoglobulin was partially purified from ascites by ammonium 
sulfate  precipitation  at  50%  saturation.  After  dialysis,  the  preparations  were  coupled  to 
Sepharose  4B  or  Sepharose  CL-4B  (Pharmacia  Fine  Chemicals,  Div.  of Pharmacia  Inc., 
Piscataway, N  J) at a ratio of 2 mg protein/ml resin (14). Glycoprotein pools isolated from  1-2 
×  l0  s cells were passed over 6 ml antibody affinity columns and the adherent antigens eluted 
using 0.05  M  diethylamine (15).  In some preparations, the  I-LR1  eluate was dialyzed and 
repassed over an I-LR 1 column. The I-LR 1-reactive antigens were usually removed by affinity 
chromatography before chromatography on the IIIE3 column. The antigens were isolated from 
the adherent pools by precipitation with acetone. 
SDS Gel Electrophoresis.  IIIE3-reactive antigens were electrophoresed under reducing condi- 
tions on  13.5% SDS gels (16).  I-LRl-reactive molecules were electrophoresed under reducing 
conditions on  12.5% gels containing twice the normal concentration of N,N'-methylene-bis- 
acrylamide (0.66% bis-acrylamide). Tube gels were fractionated into a 0.05% SDS solution, and 
aliquots were counted to determine the positions of the alpha and beta polypeptides. Preparative 
isolations of alpha and beta chains from these gels have been previously described (12). 
Amino Acid Sequence Determination.  Isolated alpha  and  beta  chains  labeled with  a  single 
Jail]amino acid were sequenced on a Beckman 890C sequencer (Beckman Instruments, Fuller- 
ton,  CA)  as previously described  (12).  Butyl  chloride fractions were evaporated  under  N2, 
scintillation fluid was added, and the radioactivity in each fraction was determined using a 
Beckman LS8100 liquid scintillation counter. 
Results 
I-LR1 and IIIE3 Recognize DR-like Molecules.  A  structural  comparison  of the  DR 
and  SB molecules was undertaken  on  the lymphoblastoid B  cell line PRIESS.  This 
cell line is phenotypically homozygous for DR4  (10)  and, although  heterozygous for 
SB3/4, expresses only one allelic product (SB3) to which the SB-selective monoclonal 
antibody, I-LR1,  is known  to bind.  Direct binding assays confirm  that  the cell line 
binds both the I-LR1 antibody and a  DR-selective monoclonal antibody, IIIE3 (12). 
Antibody affinity columns containing either I-LR 1 or IIIE3 were used to isolate the 
reactive antigens from a  PRIESS glycoprotein pool. Both antibodies bound a  bimo- 
lecular complex  that  migrated  under  reducing  conditions  in  the  molecular weight 
range of the DR  antigens on an  SDS polyacrylamide gel, confirming earlier studies 
by Nadler et al.  (9). The alpha and beta chains of the I-LRl-reactive antigens were 
difficult to separate on a  13.5% polyacrylamide gel, and a  change in the acrylamide 
concentration (12.5% acrylamide with twice the concentration of bis-acrylamide) was 
necessary to cleanly separate the alpha and beta polypeptides. 
The Amino Acid Sequences of SB Alpha and Beta  Chains Differ from  DR Alpha and Beta 
Chains. PRIESS was radiolabeled with [aH]phenylalanine and [aH]tyrosine independ- 
ently.  Alpha  and  beta  chains  were  isolated  from  the  I-LR1-  and  IIIE3-reactive 
preparations, and their amino-terminal amino acid sequences were determined. The 
results are summarized in Table I. The phenylalanine-labeled alpha chains from both 
I-LR 1 and IIIE3 preparations are identical with phenylalanine observed at positions 
12, 22, 24, and 26 in both chains. The phenylalanine-labeled SB and DR beta chains, 
on the other hand, differ. Phenylalanine is observed at positions 18 and 24 in the SB 
beta chain and at 7,  17,  18, and 26 in the DR beta chain. A  variable amount  (0-60%) 
of DR-like sequence is observed in the SB beta chain preparations depending on the 
method of isolation. If the I-LRl-reactive material is repassed over the I-LR 1 column 
in  the  presence  of  a  protein  carrier,  the  DR  contamination  is  decreased.  These 
experiments suggest that weak cross-reactivity may exist between SB and DR antigens. 
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TABLE  I 
Amino Acid Sequence Comparison of SB and DR Antigens 
Alpha chains 
Position:  9  12  13  22  24  26 
DR  --*  F  Y  F  F  F 
SB  Y  F  --  F  F  F 
Beta chains 
Position:  7  9  16  17  18  24  26  28  30  32 
DR  F  --  --  F  F  --  (17)$  --  Y  V 
SB  Y  Y  Y  --  F  F  --  Y  Y  -- 
* Indicates the absence of the assigned  amino acid at that position. 
$ Tentative assignment. 
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FIG.  l.  Linear plots of the results of two amino acids sequences of {aH]tyrosine-labeled beta chains 
from PRIESS. Above, the sequence of the DR beta chain isolated using the antibody IIIE3; below, 
the sequence of the SB beta chain isolated using the antibody I-LR 1. 
variation  is  found  in  the  alpha  chain  sequences.  The  SB  alpha  chain  contains  a 
tyrosine at position 9, whereas the DR alpha chain exhibits a  tyrosine at position  13. 
Again, depending on the method of isolation, the SB alpha chain preparation contains 
0-60% DR alpha chain contamination.  The tyrosine-labeled beta chain  is shown in 
Fig.  1. Tyrosines are observed at positions 7, 9,  16,  28, and 30 in the SB beta chain, 
whereas  the  DR  beta  chain  exhibits  tyrosines  at  positions  30  and  32.  The  slight 
variations in the IIIE3-derived beta chain baseline are insignificant (i.e., based on the 
repetitive yield of the sequencer, if a  tyrosine were present at position 7, for example, 
a  radioactive  peak  of-1,800  cpm  would  have  been  observed).  These  sequencing 
experiments demonstrate that both SB alpha and beta chains are structurally distinct 
from IIIE3-reactive DR alpha and beta chains. 
Discussion 
Both  IIIE3 and  I-LR1  monoclonal antibodies react with  DR-like molecules from 
the  human  cell  line  PRIESS.  IIIE3  appears  to  react  with  DR  antigens  and,  by 
functional  studies,  is  nonreactive with  products of the SB  locus.  By functional  and 1560  HURLEY ET AL.  BRIEF  DEFINITIVE REPORT 
cellular  binding studies,  I-LR1, on  the other hand,  appears to react  only with  the 
product of the PRIESS SB3 allele. 
The  amino  acid  sequence  data  indicate  that  both  alpha  and  beta chains  of SB 
antigens  differ from DR antigens.  The alpha chains  share  four of the six positions 
examined and, in this limited analysis, appear homologous to each other. Both chains 
have phenylalanine at positions characteristic ofmurine IoE alpha chains (but lacking 
in murine  I-A alpha chains)  (17);  thus,  both subsets appear to be I-E homologues. 
The DR and SB beta chains are very different from one another as might be expected 
if  the  beta  chains  exhibit  the  majority  of  the  observed  polymorphism  of  these 
molecules (18,  19). Because of this polymorphism, it is difficult to categorize clearly 
beta chains as being I-A- or I-E-like molecules. Both subsets have structural similarity 
to human HLA-DR chains described previously by a number of laboratories. 
Whereas the available data are consistent with the interpretation that the molecules 
isolated using I-LR1 and IIIE3 are SB3 and DR4, respectively, there are alternative 
possibilities.  It is  theoretically possible that  the  two subsets  of molecules are allelic 
products of the same locus; however, there are two lines of evidence that suggest that 
they are products of distinct loci. First, the cell line used is phenotypically homozygous 
for  DR4/4,  although  it  is  possible  that  the  two  alleles  of DR4  are  not  identical. 
Alternatively, because the cell line is heterozygous for SB, both monoclonal antibodies 
could recognize allelic products of the SB locus.  It would be surprising, however, to 
find that the structural differences between the alleles would be so dramatic. Second, 
characterization of the monoclonal antibodies indicates that the subsets are products 
of distinct  loci. I-LR 1 is known to bind to products of the SB locus but has not been 
observed  to  bind  to  molecules  bearing  DR4  determinants.  Most  relevant  in  this 
discussion  is the finding that I-LR1 binds to the SB3 allelic product of the cell line 
PRIESS, as indicated by its ability to specifically block proliferation of SB3- (but not 
SB4-) specific responses to PRIESS. In contrast, the monoclonal IIIE3 preferentially 
binds gene products associated with DR antigens which are lost in a DR null mutant 
(S.  Shaw and R.  DeMars,  personal communication).  In addition,  IIIE3 and  I-LR1 
also appear to recognize structurally distinct molecules from an HLA hemizygous cell 
line (C. Hurley and R. DeMars, personal communication). 
Although these lines of evidence suggest that the SB and DR subsets are products 
of distinct  loci, only the second,  the characterization  of the monoclonal  antibodies, 
indicates  that  the  I-LR1- and  IIIE3-reactive pools  correspond  to  SB  and  DR.  At 
present this is the most likely hypothesis. In particular,  it is certain both subsets are 
distinct  from the DC/MT/DS  product on the basis of sequence  (20).  However, it is 
possible that,  in  particular,  the  I-LRl-reactive subset  represents  a  fourth  family of 
molecules  (distinct  from  DR,  SB,  and  MT/DC/DS).  Because  I-LR1  appears  to 
recognize epitopes on at least two DR-like molecules (SB2, SB3, and DR5)  (8), it is 
possible that it can occasionally recognize products of yet another locus. The present 
data provide no evidence for this hypothesis, but it cannot be formally excluded. 
Although the SB antigen appears to be I-E-like based on its alpha chain sequence, 
the  large  extent  of sequence  divergence  between  the  SB  and  DR  beta  chains  is 
surprising.  Using  amino-terminal  amino  acid  sequence  analysis,  the  presence  of 
structurally  distinct  I-E-like DR beta chains  has been noted  (12,  21,  22);  however, 
individual  I-E-like beta chains  isolated using monoclonal antibodies have appeared 
to be structurally very similar (12).  This suggests that either the loci encoding the SB 
and DR beta chains may have diverged earlier in evolution  than  the loci encoding 
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molecular  species.  Further  comparisons  between  the  SB  and  DR  beta  chains  will 
answer this question. 
These data provide the first evidence for two structurally distinct nonallelic I-E-like 
alpha  chains  in  the  human.  Multiple  D  region  alpha  chains  have  been  previously 
proposed  (23-26);  however,  the  two  alpha  chains  identified  in  those  studies  may 
represent  the I-A and I-E alpha chain homologues (20)  rather than multiple I-E-like 
molecules.  The  presence  of two  I-E-like  alpha  chains  is  interesting,  as  published 
studies using DR alpha chain DNA probes suggest that there is a single I-E-like alpha 
chain  locus  (27,  28).  The  presence  of structurally  distinct  but  related  SB  and  DR 
alpha  chains  suggests  that  either  the  SB  and  DR  alpha  chain  genes  are  different 
enough not to cross-hybridize or they share identical restriction sites and appear as a 
single  restriction  fragment,  as  has  been  suggested  for some  of the  members  of the 
murine H2 gene family (29). The SB and DR alpha chains could, therefore, be very 
different as are the SB and DR beta chains or, alternatively,  the chains are so similar 
in  structure  that  even  the  nontranslated  regions  of DNA surrounding  the  two  loci 
share extensive homology. A  closer examination of the SB and DR gene products is 
currently underway to determine the extent of variability present in these two sets of 
HLA-D region antigens. 
Summary 
Limited amino-terminal amino acid sequences of the HLA-controlled SB and DR 
antigens  from the  cell  line  PREISS  (DR4/4,  SB3/4)  show  differences  in  both  the 
alpha and beta chain sequences of the two molecules. SB antigens, like DR antigens, 
appear to be homologues of the murine I-E antigens. 
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